addiction, cocaine, relapse, dopamine, DA D2 receptor, rimonabant, dopamine, neuro-imaging, SPECT, fMRI
Conditions
Interventions
Rimonabant or placebo will be administered for 2 months. [123I]IBZM SPECT will be performed at baseline and at the end of the experiment to assess the prolonged effects of rimonabant on DA D2 receptor
Sponsors
Prof. dr. Wim Van den Brink
dr. Jan Booij
dr. Michelle Miller
drs. Cleo Crunelle
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male, age 18-60 years 2. Current DSM-IV diagnosis of cocaine dependence, but recently detoxified and abstinent 3. Able to provide written informed consent and to comply with all study procedures.
Exclusion criteria
Exclusion criteria: 1. Currently dependent on any substance other than cocaine or nicotine 2. History of depression that could be defined as even a single episode or recurrent episodes of depression, or depression necessitating hospitalization, or history of suicide attempt (see fotenote1) 3. Severe neurological or psychiatric disorders (e.g., psychosis, bipolar illness, dementia, or any diseases that require psychotropic medications) 4. Serious medical illnesses 5. Known hypersensitivity or allergy to rimonabant, or receiving chronic therapy with medication that could interact adversely with one of the medications under study, within 30 days prior to randomization 6. Drugs known to influence binding to DA2 receptors, including neuroleptics, and methylphenidate 7. Received a drug with known potential for toxicity to a major organ system within the month prior to entering treatment 8. Clinically significant abnormal laboratory values, as measured by the treatment centre 9. Any disease of the gastrointestinal system, liver, or kidneys which could result in altered metabolism or excretion of the study medication 10. Hypersensitivity to Jodium
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the changes in DA D2 receptor availability in the striatum after 2 months of rimonabant treatment. To assess whether rimonabant can decrease cocaine craving and/or impulsivity in human cocaine users. To assess whether DA D2 receptor availability in the striatum can predict relapse to cocaine abuse in detoxified cocaine users. | — |
Contacts
Public ContactCleo L. Crunelle
Academic Medical Center, University of Amsterdam Amsterdam Institute for Addiction Research Department of Psychiatry, PB0-436 P.O. Box 75867
Outcome results
None listed